Harvard Women's Health Watch

Another drug prevents breast cancer in postmenopausal women

Exemestane (Aromasin), tamoxifen (Nolvadex, generic) and raloxifene (Evista) are three drugs used to prevent breast cancer in postmenopausal women who are at elevated risk for the disease. Exemestane appears to have less frightening side effects — hot flashes, joint pain, and loss of bone density. All three of these drugs target estrogen, which fuels the growth of most breast cancers, but exemestane belongs to a different class of drugs, called aromatase inhibitors, which work by blocking the body's production of estrogen. Previous studies have shown that aromatase inhibitors are more effective than tamoxifen in preventing breast cancer from recurring. This study, funded Pfizer, and conducted under the auspices of the National Cancer Institute's clinical trials unit, looked at whether exemestane could reduce the likelihood of a first occurrence of breast cancer.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »